Follow-up of children exposed in utero to 17 α-hydroxyprogesterone caproate compared with placebo

Obstetrics and Gynecology

Volumn 110, Issue 4, 2007, Pages 865-872

  Northen, Allison T ^a   Norman, Gwendolyn S ^b   Anderson, Kristine ^b   Moseley, Lisa ^b   DiVito, Michelle ^b   Cotroneo, Margaret ^b   Swain, Melissa ^b   Bousleiman, Sabine ^b   Johnson, Francee ^b   Dorman, Karen ^b   Milluzzi, Cynthia ^b   Tillinghast, Jo Ann ^b   Kerr, Marcia ^b   Mallett, Gail ^b   Thom, Elizabeth ^b   Pagliaro, Susan ^b   Anderson, Garland D ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; PLACEBO;

ADULT; ARTICLE; CHILD; CHILD DEVELOPMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTORCHISM; DEVELOPMENTAL DISORDER; DEVELOPMENTAL SCREENING; DEVELOPMENTAL STAGE; DRUG SAFETY; FEMALE; FOLLOW UP; GENITAL MALFORMATION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; MEDICAL ASSESSMENT; MICROPENIS; PHYSICAL DISABILITY; PHYSICAL EXAMINATION; PRENATAL DRUG EXPOSURE; PRESCHOOL ACTIVITIES INVENTORY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

CHILD DEVELOPMENT; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYPROGESTERONES; INFANT, NEWBORN; NERVOUS SYSTEM; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PRENATAL EXPOSURE DELAYED EFFECTS; PROGESTINS;

EID: 34848921181     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000281348.51499.bc     Document Type: Article

References (23)

1. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate [published erratum appears in N Engl J Med 2003;349:1299]. N Engl J Med 2003;348:2379-85.
2. Ehrhardt AA, Money J. Progestin-induced hermaphroditism: IQ and psychosexual identity in a study of ten girls. J Sex Res 1967;3:83-100.
3. Kester P, Green R, Finch SJ, Williams K. Prenatal "female hormone" administration in psychosexual development in human males. Psychoneuroendocrinology 1980;5:269-85.
4. Dalton K. Ante-natal progesterone and intelligence. Br J Psychiatry 1968;114:1377-82.
5. Dalton K. Prenatal progesterone and educational attainments. Br J Psychiatry 1976;129:438-42.
6. Reinisch JM. Prenatal exposure of human foetuses to synthetic progestin and oestrogen affects personality. Nature 1977;266:561-2.
7. Squires J, Potter L, Bricker D. The ASQ user's guide. 2nd ed. Baltimore (MD): Paul H. Brookes; 1999.
8. Golombok S, Rust J. The Pre-School Activities Inventory (PSAI): a standardized assessment of gender role in children. Psychol Assess 1993;5:131-6.
9. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11 2002 May;246:1-190.
10. Roche AF, Mukherjee D, Guo S, Moore WM. Head circumference reference data: birth to 18 years. Pediatrics 1987;79:706-12.
11. Johnstone EE, Franklin RR. Assay of progestins for fetal virilizing properties using the mouse. Obstet Gynecol 1964;23:359-62.
12. Seegmiller RE, Nelson GW, Johnson CK. Evaluation of the teratogenic potential of Delalutin (17 alpha-hydroxyprogesterone caproate) in mice. Teratology 1983;28:201-8.
13. Carbone JP, Brent RL. Genital and nongenital teratogenesis of prenatal progesterone therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B 1/6J mouse. Am J Obstet Gynecol 1993;169:1292-8.
14. Kessler W, Borman A. Some biological activities of certain progestogens. I. 17 alpha-Hydroxyprogesterone 17-n-caproate. Ann N Y Acad Sci 1958;71:486-93.
15. Goldman AS, Bongiovanni AM. Induced genital anomalies. Ann NY Acad Sci 1967;142:755-67.
16. Courtney KD, Valerio DA. Teratology in the Macaca mulatta. Teratology 1968;1:163-72.
17. Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 1980;22:251-70.
18. Sanfilippo JS Labial adhesions. In: Behrman RE, Kliegman RM, Jenson HB. Nelson textbook of pediatrics. 17th ed. Philadelphia (PA): WB Saunders; 2004. p. 1829-30.
19. Michaelis J, Michaelis H, Gluck E, Koller S. Prospective studies of suspected association between certain drugs administered during early pregnancy and congenital malformations Teratology 1983;27:57-64.
20. Resseguie LJ, Hick JF, Bruen JA, Noller KL, O'Fallon WM, Kurland LT. Congenital malformations among offspring exposed in utero to progestins, Olmstead County, Minnesota 1936-1974. Fertil Steril 1985;43:514-9.
21. Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 1985;65:775-80.
22. Check JH, Rankin A, Teichman M. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril 1986;45:575-7.
23. Kester PA. Effects of prenatally administered 17 alpha- hydroxyprogesterone caproate on adolescent males. Arch Sex Behav 1984;13:441-55.